NCT05562934 is a Phase 2 clinical trial of XXB750 drug in Resistant Hypertension, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT05562934?

NCT05562934 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05562934?

Interventions in NCT05562934: XXB750 drug, Placebo.

What condition does NCT05562934 study?

NCT05562934 studies Resistant Hypertension.

Is NCT05562934 still recruiting?

NCT05562934 is currently completed. Last updated 12 January 2026.

Are results published for NCT05562934?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-01-12 · How we verify

NCT05562934

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Completed Phase 2 Results posted Last updated 12 January 2026

What this trial tests

Phase 2 trial testing XXB750 drug in Resistant Hypertension in 189 participants. Completed in 27 August 2024.

Timeline

8 November 2022

Primary endpoint
2 July 2024

27 August 2024

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	189
Start date	8 November 2022
Primary completion	2 July 2024
Estimated completion	27 August 2024
Sites	78 locations across France, Italy, Japan, Netherlands, Slovakia, Austria, Taiwan, United Kingdom

Drugs / interventions tested

XXB750 drug — full drug profile →
Placebo

Conditions studied

Resistant Hypertension — all drugs for Resistant Hypertension →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 100, any sex, with Resistant Hypertension. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Dose-response (DR) Relationship of XXB750 With Respect to Change From Baseline in Systolic Blood Pressure (SBP) 24 Hours Primary · Baseline, Week 12

To evaluate the efficacy and dose-response relationship of different doses of XXB750 compared to placebo in reducing the mean 24 hours ambulatory systolic blood pressure from baseline at Week 12. Automated arterial BP determinations and pulse rate readings were made with Microlife Watch BP Office 2G, an automated digital BP device. The primary outcome measure was evaluated using an optimally weighted contrast test following the Multiple Comparison Procedure-Modeling (MCP-MOD) methodology. There were five candidate models to capture the shape of the dose-response relationship for XXB750 at Week

Group	Value	95% CI
Placebo	-5.77	-10.74 – -1.12
XXB750 30 mg	-6.41	-10.15 – -2.85
XXB750 60 mg	-6.63	-10.40 – -3.53
XXB750 120 mg	-6.66	-12.57 – -3.16
XXB750 120 mg/240 mg	-5.40	-9.58 – -0.36

Change From Baseline in SBP 24 Hours at Week 12 (Difference Between Highest XXB750 Dose and Placebo) Secondary · Baseline, Week 12

To evaluate the treatment effect of the highest XXB750 dose versus placebo in reducing the mean 24 hours SBP from baseline to Week 12. Automated arterial BP determinations and pulse rate readings were made with Microlife Watch BP Office 2G, an automated digital BP device.

Group	Value	95% CI
Placebo	-6.01	± 2.42
XXB750 120 mg/240 mg	-4.64	± 2.49

Change From Baseline in SBP 24 Hours of Average of Week 9 and Week 12 (Difference Between Highest XXB750 Dose and Placebo) Secondary · Baseline, Week 9 and Week 12

To evaluate the treatment effect of the highest XXB750 dose versus placebo in the dosing interval average of ambulatory SBP as assessed by average of mean 24 hours SBP measured at week 9 and week 12. Automated arterial BP determinations and pulse rate readings were made with Microlife Watch BP Office 2G, an automated digital BP device.

Group	Value	95% CI
Placebo	-5.77	± 2.13
XXB750 120 mg/240 mg	-4.62	± 2.21

The Model-based Estimated Percentage of Participants Achieving Blood Pressure (BP) Control Secondary · Week 12

To evaluate the percentage of participants achieving ambulatory BP control defined as mean 24 hours SBP \<130 mmHg and mean 24 hours DBP \< 80 mmHg with respect to the dose-response relationship of the four XXB750 dose level groups compared to placebo at week 12. Automated arterial BP determinations and pulse rate readings were made with Microlife Watch BP Office 2G, an automated digital BP device. Percentage of participants is derived from dose response analysis, using generalized MCP-Mod methodology for binary data.

Group	Value	95% CI
Placebo	13.2
XXB750 30 mg	15.0
XXB750 60 mg	17.7
XXB750 120 mg	22.0
XXB750 120 mg/240 mg	25.9

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period, up to a maximum duration of approximately 20 weeks.. Reporting threshold: 2%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 1/42 (2%)

Deaths: 0/42

XXB750 30 mg

Serious: 2/32 (6%)

Deaths: 0/32

XXB750 60 mg

Serious: 3/36 (8%)

Deaths: 0/36

XXB750 120 mg

Serious: 1/37 (3%)

Deaths: 0/37

XXB750 120 mg/240 mg

Serious: 3/42 (7%)

Deaths: 0/42

Serious adverse events (13 terms)

Reaction	System	Placebo	XXB750 30 mg	XXB750 60 mg	XXB750 120 mg	XXB750 120 mg/240 mg
Pneumonia	Infections and infestations	—	—	—	—	—
Cardiac failure	Cardiac disorders	—	—	—	—	—
Coronary artery disease	Cardiac disorders	—	—	—	—	—
Device related infection	Infections and infestations	—	—	—	—	—
Infectious pleural effusion	Infections and infestations	—	—	—	—	—
Osteomyelitis acute	Infections and infestations	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—
Exertional rhabdomyolysis	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Plasma cell myeloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—
Syncope	Nervous system disorders	—	—	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—	—	—

Other adverse events (140 terms — click to expand)

Reaction	System	Placebo	XXB750 30 mg	XXB750 60 mg	XXB750 120 mg	XXB750 120 mg/240 mg
COVID-19	Infections and infestations	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—	—
Prothrombin time prolonged	Investigations	—	—	—	—	—
Hyperkalaemia	Metabolism and nutrition disorders	—	—	—	—	—
Hyperlipidaemia	Metabolism and nutrition disorders	—	—	—	—	—
Hyperuricaemia	Metabolism and nutrition disorders	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—
Proteinuria	Renal and urinary disorders	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—
Iron deficiency anaemia	Blood and lymphatic system disorders	—	—	—	—	—
Angina pectoris	Cardiac disorders	—	—	—	—	—
Bradycardia	Cardiac disorders	—	—	—	—	—
Cardiac failure	Cardiac disorders	—	—	—	—	—
Diastolic dysfunction	Cardiac disorders	—	—	—	—	—
Left ventricular hypertrophy	Cardiac disorders	—	—	—	—	—
Myocardial ischaemia	Cardiac disorders	—	—	—	—	—
Palpitations	Cardiac disorders	—	—	—	—	—
Sinus bradycardia	Cardiac disorders	—	—	—	—	—
Supraventricular extrasystoles	Cardiac disorders	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—
Eyelid oedema	Eye disorders	—	—	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—
Influenza like illness	General disorders	—	—	—	—	—
Injection site pain	General disorders	—	—	—	—	—
Injection site pruritus	General disorders	—	—	—	—	—

Most-reported serious reactions: Pneumonia, Cardiac failure, Coronary artery disease, Device related infection, Infectious pleural effusion, Osteomyelitis acute, Dehydration, Hypokalaemia.

Data from ClinicalTrials.gov NCT05562934 adverse events section.

Sponsor's own description

The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC) injections, compared to placebo. Since all study participants will be patients with rHTN, all study treatments will be given on top of maximally tolerated background antihypertensive therapy recommended by international guidelines for treatment of HTN (i.e., a thiazide or a thiazide-like diuretic, an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), and a long-acting dihydropyridine calcium channel blocker (CCB).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension: A Randomized Phase 2 Trial.
White WB, Azizi M, Ferdinand K, Cohen DL, et al · · 2026 · cited 1× · PMID 41563174 · DOI 10.1016/j.jacc.2025.11.045

Verify or expand the search:

Other recruiting trials for Resistant Hypertension

Currently open trials in the same condition.

NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
NCT07081243 — Symplicity China Study · recruiting
NCT07207226 — Arterial Stiffness as a Tool to Investigate Adherence in Resistant Hypertension · NA · recruiting
NCT06526858 — Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant · NA · recruiting
NCT05888233 — Allopurinol Improves Heart Function in African Americans With Resistant Hypertension · Phase 2 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05562934 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 12 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05562934.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing